Risk of cardiomyopathy associated with (A) daunorubicin and (B) mitoxantrone relative to doxorubicin. Markers and extending 95% confidence intervals for each agent represents estimates from a Cox proportional hazards model based on categorical dose increments. Each marker is placed at the median dose on the x-axis for each category. Lines represent the linear (solid) and linear exponential (dashed) modeled continuous dose-response relationships. From Feijen et al.^11,12